Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis

The European respiratory journal. Supplement Pub Date : 2019-12-01 DOI:10.1183/13993003.01188-2019

M. Kreuter, D. Lederer, V. Cottin, N. Kahn, B. Ley, C. Vancheri, D. Weycker, M. Atwood, K. Kirchgaessler, C. Ryerson

{"title":"Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis","authors":"M. Kreuter, D. Lederer, V. Cottin, N. Kahn, B. Ley, C. Vancheri, D. Weycker, M. Atwood, K. Kirchgaessler, C. Ryerson","doi":"10.1183/13993003.01188-2019","DOIUrl":null,"url":null,"abstract":"Patients with idiopathic pulmonary fibrosis (IPF) frequently have a substantial burden of comorbidities [1]. Antifibrotic therapy is recommended to slow the progression of IPF [2]. Patients receiving antifibrotic therapy frequently receive concomitant medications for the management of comorbidities [1, 3–9]. Previous post hoc analyses of antacids, statins, metformin, anticoagulants and angiotensin modulators in patients with IPF enrolled in phase III randomised controlled trials (RCTs) have generated hypotheses on the impact of these treatments on IPF outcomes [3–9]. The effects of multiple concomitant medications in patients with IPF have been largely unexplored. The objective of the present analyses was to explore the association between use of combinations of frequently prescribed concomitant medications and disease outcomes in patients with IPF. This post hoc exploratory analysis found no clear associations between frequently used concomitant medication combinations and disease progression in 1450 patients with IPF enrolled in phase III trials, but several combinations may require further study. http://bit.ly/2ZzyMXR","PeriodicalId":77419,"journal":{"name":"The European respiratory journal. Supplement","volume":"93 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European respiratory journal. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.01188-2019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 9

Abstract

Patients with idiopathic pulmonary fibrosis (IPF) frequently have a substantial burden of comorbidities [1]. Antifibrotic therapy is recommended to slow the progression of IPF [2]. Patients receiving antifibrotic therapy frequently receive concomitant medications for the management of comorbidities [1, 3–9]. Previous post hoc analyses of antacids, statins, metformin, anticoagulants and angiotensin modulators in patients with IPF enrolled in phase III randomised controlled trials (RCTs) have generated hypotheses on the impact of these treatments on IPF outcomes [3–9]. The effects of multiple concomitant medications in patients with IPF have been largely unexplored. The objective of the present analyses was to explore the association between use of combinations of frequently prescribed concomitant medications and disease outcomes in patients with IPF. This post hoc exploratory analysis found no clear associations between frequently used concomitant medication combinations and disease progression in 1450 patients with IPF enrolled in phase III trials, but several combinations may require further study. http://bit.ly/2ZzyMXR

查看原文本刊更多论文

特发性肺纤维化的伴随药物治疗和临床结果

特发性肺纤维化(IPF)患者经常有大量的合并症。抗纤维化治疗被推荐用于减缓IPF bbb的进展。接受抗纤维化治疗的患者经常同时接受药物治疗以控制合并症[1,3 - 9]。先前对III期随机对照试验(RCTs)中IPF患者的抗酸药、他汀类药物、二甲双胍、抗凝剂和血管紧张素调节剂的事后分析已经对这些治疗对IPF结局的影响产生了假设[3-9]。多种合用药物对IPF患者的影响在很大程度上尚未得到探索。本分析的目的是探讨IPF患者常用联合用药与疾病结局之间的关系。这项事后探索性分析发现，在1450名参加III期试验的IPF患者中，常用的联合用药与疾病进展之间没有明确的关联，但一些联合用药可能需要进一步研究。http://bit.ly/2ZzyMXR

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The European respiratory journal. Supplement

自引率

0.00%

发文量